We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current PMCB market cap is 12.29M. The company's latest EPS is USD -2.2447 and P/E is -0.71.
| Quarter End | Jul 2023 | Oct 2023 | Jan 2024 | Apr 2024 | Jul 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -2.08M | -1.41M | -1.87M | -3.17M | -1.27M |
| Net Income | -3.5M | -5.53M | -5.66M | -2.54M | 20.59M |
| Year End April 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -3.83M | -3.62M | -4.39M | -6.46M | -8.52M |
| Net Income | -3.83M | -3.55M | -4.24M | -4.32M | -17.24M |
| Quarter End | Jul 2023 | Oct 2023 | Jan 2024 | Apr 2024 | Jul 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 79.88M | 78.88M | 71.36M | 59.9M | 70.19M |
| Total Liabilities | 20.4M | 20.81M | 22.47M | 20.39M | 17.15M |
| Total Equity | 42.73M | 36.77M | 31.38M | 27.65M | 47.71M |
| Year End April 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 6.17M | 7.4M | 90.62M | 73.28M | 59.9M |
| Total Liabilities | 1.08M | 725k | 704k | 587k | 20.39M |
| Total Equity | 5.09M | 6.68M | 89.92M | 72.69M | 27.65M |
| Quarter End | Jul 2023 | Oct 2023 | Jan 2024 | Apr 2024 | Jul 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 344k | -1.64M | -1.82M | -2.15M | -373k |
| Investing | N/A | N/A | -5M | -5M | -7M |
| Financing | 6.28M | 7.03M | -11k | -10.71M | -10.17M |
| Year End April 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -2.34M | -3.33M | -4.12M | -3.79M | -2.15M |
| Investing | N/A | N/A | N/A | N/A | -5M |
| Financing | 2.73M | 4.64M | 87.31M | -13.56M | -10.71M |
| Market Cap | 12.29M |
| Price to Earnings Ratio | -0.71 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 0.24 |
| Price to Book Ratio | 0.31 |
| Dividend Yield | - |
| Shares Outstanding | 7.68M |
| Average Volume (1 week) | 14.67k |
| Average Volume (1 Month) | 56.28k |
| 52 Week Change | -20.79% |
| 52 Week High | 2.58 |
| 52 Week Low | 1.39 |
| Spread (Intraday) | 0.08 (5%) |
| Company Name | PharmaCyte Biotech Inc |
| Address |
401 ryland st ste 200-a reno, nevada 89502 |
| Website | https://ir.pharmacyte.com |
| Industry | medicinal chems,botanicl pds (2833) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
